MedPath

UNIVERSITY OF SOUTHERN CALIFORNIA

UNIVERSITY OF SOUTHERN CALIFORNIA logo
🇺🇸United States
Ownership
Private
Established
1880-01-01
Employees
10K
Market Cap
-
Website
http://startusc.com

Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening

Not Applicable
Completed
Conditions
Cervical Cancer
Interventions
Behavioral: Questionnaire
First Posted Date
2014-10-15
Last Posted Date
2015-12-02
Lead Sponsor
University of Southern California
Target Recruit Count
1000
Registration Number
NCT02265120
Locations
🇺🇸

USC Sol Price School of Public Policy, Los Angeles, California, United States

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Phase 2
Completed
Conditions
Insulinoma
Gastrinoma
Recurrent Gastrointestinal Carcinoid Tumor
Pancreatic Polypeptide Tumor
Pulmonary Carcinoid Tumor
Somatostatinoma
Glucagonoma
Metastatic Gastrointestinal Carcinoid Tumor
Recurrent Islet Cell Carcinoma
Interventions
Drug: regorafenib
Other: laboratory biomarker analysis
First Posted Date
2014-10-08
Last Posted Date
2021-12-15
Lead Sponsor
University of Southern California
Target Recruit Count
3
Registration Number
NCT02259725
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 2 locations

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

Not Applicable
Withdrawn
Conditions
Stage IA Non-small Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Interventions
Radiation: stereotactic radiosurgery
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: quality-of-life assessment
First Posted Date
2014-09-26
Last Posted Date
2015-09-16
Lead Sponsor
University of Southern California
Registration Number
NCT02250378
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide

Withdrawn
Conditions
Small Cell Lung Cancer
Interventions
Other: cytology specimen collection procedure
Other: laboratory biomarker analysis
First Posted Date
2014-09-26
Last Posted Date
2018-05-25
Lead Sponsor
University of Southern California
Registration Number
NCT02250404
Locations
🇺🇸

Los Angeles County-USC Medical Center, Los Angeles, California, United States

🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Core Biopsies for Establishing a Breast Tumor Tissue Repository

Recruiting
Conditions
Breast Cancer
Interventions
Other: cytology specimen collection procedure
First Posted Date
2014-09-26
Last Posted Date
2023-11-18
Lead Sponsor
University of Southern California
Target Recruit Count
1450
Registration Number
NCT02250352
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Use of a Microbial Sealant to Reduce Surgical Site Infections.

Phase 4
Completed
Conditions
Surgical Site Infection
SCIP
Interventions
Procedure: Open Colorectal Surgery
Procedure: Laparoscopic Surgery
First Posted Date
2014-09-16
Last Posted Date
2014-09-16
Lead Sponsor
University of Southern California
Target Recruit Count
100
Registration Number
NCT02241915
Locations
🇺🇸

Los Angeles County/USC Medical Center, Los Angeles, California, United States

Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

Not Applicable
Completed
Conditions
Adenocarcinoma of the Prostate
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Interventions
Procedure: diffusion-weighted magnetic resonance imaging
Other: laboratory biomarker analysis
First Posted Date
2014-09-11
Last Posted Date
2014-09-11
Lead Sponsor
University of Southern California
Target Recruit Count
9
Registration Number
NCT02237612
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

Phase 2
Withdrawn
Conditions
Recurrent Colon Cancer
Signet Ring Adenocarcinoma of the Colon
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Stage IVB Colon Cancer
Stage IVB Rectal Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Rectum
Interventions
Biological: ziv-aflibercept
Drug: leucovorin calcium
Drug: fluorouracil
Other: laboratory biomarker analysis
First Posted Date
2014-09-09
Last Posted Date
2015-05-06
Lead Sponsor
University of Southern California
Registration Number
NCT02235324
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Social Work Intervention Focused on Transitions

Not Applicable
Completed
Conditions
Asthma
Stroke
Heart Disease
Diabetes
Cancer
Depression
Chronic Heart Failure
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention
Hypertension
Chronic Obstructive Pulmonary Disease
Interventions
Other: SWIFT home intervention
First Posted Date
2014-09-05
Last Posted Date
2023-11-09
Lead Sponsor
University of Southern California
Target Recruit Count
181
Registration Number
NCT02232126
Locations
🇺🇸

Huntington Hospital, Pasadena, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

Completed
Conditions
Multiple Sclerosis
Interventions
Drug: Gilenya
First Posted Date
2014-08-26
Last Posted Date
2018-08-22
Lead Sponsor
University of Southern California
Target Recruit Count
125
Registration Number
NCT02225977
Locations
🇺🇸

University of Southern California, Department of Neurology, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath